待处理
入排:排除
图源:待检查
Re: Maria De Santis, Joan Palou Redorta, Hiroyuki Nishiyama, et al. Durvalumab in Combination with BCG for BCG-naive, High-risk, Non-muscle-invasive Bladder Cancer (POTOMAC): Final Analysis of a Randomised, Open-label, Phase 3 trial. Lancet 2025;406:2221-34.
Renate Pichler, José Daniel Subiela, Félix Guerrero-Ramos
Eur Urol 89(6) e147-e148
摘要
摘要
无摘要
KM 提取结果
0 个 Figure · 0 个 KM 面板